BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The company Novo Nordisk A/S submitted on 2 July 2001 an application for Marketing Authorisation 
to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for  Insulatard,  in 
accordance with the centralised procedure falling within the scope of Part A of the Annex to Council 
Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  M. Ainsworth 
Co-Rapporteur: 
P. Nilsson 
Licensing status: 
At the time of submission of the application for Marketing Authorisation, Insulatard had been given a 
Marketing Authorisation in the majority of EU Member States under Mutual Recognition or National 
Procedures: 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 17 July 2001 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  Members  on  26 
September  2001.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP 
Members on 26 September 2001 
During  the  meeting  on  13-15  November  2001  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the company. The final consolidated List of Questions was sent to the 
company on 15 November 2001. 
The company submitted the responses to the consolidated List of Questions on 18 January 2002 
The  Rapporteur  and  the  Co-Rapporteur  circulated  the  Joint  Assessment  Report  on  the 
company’s responses to the List of Questions to all CPMP members on 22 February 2002 
During the meeting on 19-21 March 2002 the CPMP agreed on a list of outstanding issues. 
The company submitted additional information on 25 March 2002. 
The  Rapporteur  and  the  Co-Rapporteur  circulated  the  response  Assessment  Report  on  the 
company’s additional information on 15 April 2002. 
During the meeting on 23-25 April 2002 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Insulatard on 25 April 2002. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 7 October 2002. 
1/1 
EMEA 2004 
 
 
 
